Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 11Lymphoma, Non-Hodgkin 2Lymphoma 2Neoplasms, Plasma Cell 1Immunoglobulin Light-chain Amyloidosis 1Hodgkin Disease 1Amyloidosis 1

Interventions

Dexamethasone 111Cyclophosphamide 99Melphalan 91Bortezomib 69Peripheral Blood Stem Cell Transplantation 64Lenalidomide 58fludarabine phosphate 56Busulfan 54Filgrastim 50Tacrolimus 38Antilymphocyte Serum 38Thalidomide 36Radiotherapy 36Mycophenolic Acid 33fludarabine 28Cyclosporine 26Methotrexate 25Etoposide 22Calcium Dobesilate 22Whole-Body Irradiation 21Prednisone 21Methylprednisolone 20sargramostim 19pomalidomide 19Granulocyte Colony-Stimulating Factor 18carfilzomib 16daratumumab 15Cord Blood Stem Cell Transplantation 15Carmustine 14Rituximab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Plasma Cell × pegfilgrastim × Plasma cell × Clear all
NCT00526734 2013-08-12

High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Unknown
100 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡